Table 1 Clinical characteristics of patients with HER2-mutant lung cancers
From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Clinical characteristics | Total (n = 572) | HER2 negative (n = 543) | HER2 positive (n = 29) | P value |
|---|---|---|---|---|
Age, years (median,range) | 64(27–92) | 64(27–92) | 58(44–77) | 0.017 |
< 65 | 305(53.3%) | 283(52.1%) | 22(75.9%) | |
≥ 65 | 267(46.7%) | 260(47.9%) | 7(24.1%) | |
Gender | ||||
Male | 430(75.2%) | 417(76.8%) | 13(44.8%) | <0.001 |
Female | 142(24.8%) | 126(23.2%) | 16(55.2%) | |
Smoking status | ||||
Non-smoker | 305(53.3%) | 284(52.3%) | 21(72.4%) | 0.034 |
Smoker | 267(46.7%) | 259(47.7%) | 8(27.6%) | |
Histology | ||||
Adenocarcinoma | 429(75%) | 400(74.0%) | 29(100%) | 0.002 |
Non-Adenocarcinoma | 143(25%) | 117(21.3%) | 0 | |